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Liver Transplantation

Improved Survival With Higher-risk Donor Grafts
in Liver Transplant With Acute-on-chronic
Liver Failure
Toshihiro Kitajima, MD, PhD,1 Yasutaka Kuno, MD,1 Tommy Ivanics, MD,1 Mei Lu, PhD,3 Dilip Moonka, MD,2
Shingo Shimada, MD,1 Tayseer Shamaa, MD,1 Marwan S. Abouljoud, MD,1 and Shunji Nagai, MD, PhD1
Background. Use of higher-risk grafts in liver transplantation for patients with acute-on-chronic liver failure (ACLF) has
been associated with poor outcomes. This study analyzes trends in liver transplantation outcomes for ACLF over time based
on the donor risk index (DRI). Methods. Using the Organ Procurement and Transplantation Network and the United
Network for Organ Sharing registry, 17 300 ACLF patients who underwent liver transplantation between 2002 and 2019
were evaluated. Based on DRI, adjusted hazard ratios for 1-y patient death were analyzed in 3 eras: Era 1 (2002–2007,
n = 4032), Era 2 (2008–2013, n = 6130), and Era 3 (2014–2019, n = 7138). DRI groups were defined by DRI <1.2, 1.2–1.6,
1.6–2.0, and >2.0. Results. ACLF patients had significantly lower risks of patient death within 1 y in Era 2 (adjusted
hazard ratio, 0.69; 95% confidence interval, 0.61-0.78; P < 0.001) and Era 3 (adjusted hazard ratio, 0.48; 95% confidence
interval, 0.42-0.55; P < 0.001) than in Era 1. All DRI groups showed lower hazards in Era 3 than in Era 1. Improvement of
posttransplant outcomes were found both in ACLF-1/2 and ACLF-3 patients. In ACLF-1/2, DRI 1.2 to 1.6 and >2.0 had
lower adjusted risk in Era 3 than in Era 1. In ACLF-3, DRI 1.2 to 2.0 had lower risk in Era 3. In the overall ACLF cohort, the 2
categories with DRI >1.6 had significantly higher adjusted risks of 1-y patient death than DRI <1.2. When analyzing hazards
in each era, DRI > 2.0 carried significantly higher adjusted risks in Eras 1 and 3‚ whereas DRI 1.2 to 2.0 had similar adjusted
risks throughout eras. Similar tendency was found in ACLF-1/2. In the non-ACLF cohort, steady improvement of posttransplant outcomes was obtained in all DRI categories. Similar results were obtained when only hepatitis C virus-uninfected
ACLF patients were evaluated. Conclusions. In ACLF patients, posttransplant outcomes have significantly improved,
and outcomes with higher-risk organs have improved in all ACLF grades. These results might encourage the use of higherrisk donors in ACLF patients and provide improved access to transplant.
(Transplantation Direct 2022;8: e1283; doi: 10.1097/TXD.0000000000001283).
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INTRODUCTION
Acute-on-chronic liver failure (ACLF) is a succinctly defined,
systemic syndrome characterized by acute clinical deterioration in the setting of cirrhosis, development of organ failure
(OF)‚ and high 28-d mortality.1,2 ACLF grade 3 (ACLF-3),
defined by the presence of 3 or more OFs, has an especially
pronounced short-term mortality that can approach 80% at
28 d.1,3 Liver transplantation (LT) represents the only opportunity for long-term survival in many of these patients.4-6
Timely LT is critical because of the high waitlist mortality,
especially in ACLF-3 patients, and because ACLF-3 patients
who undergo LT within 30 d have better outcomes than those
who wait longer.7 The use of higher-risk donor grafts might
be one option to facilitate expedient LT; however, marginal or
high donor risk index (DRI) grafts, historically, have resulted in
suboptimal posttransplant outcomes in ACLF patients.7,8 One
study found that a DRI >1.7 was independently associated with
decreased 1-y survival in patients with ACLF-3.7 The use of
marginal grafts for ACLF patients remains of imprecise benefit
in that the risks associated with these grafts might outweigh the
benefit of LT, especially in ACLF patients with multiple OFs.7,9
The use of higher-risk donor grafts has increased in the general liver transplant population over time. The outcomes with
www.transplantationdirect.com
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these grafts have improved because of several factors, including increased center experience combined with advances in
surgical and medical care10; however, no studies have assessed
the effect of this trend on posttransplant outcomes in ACLF
patients. It remains unclear whether thresholds for utilizing higher-risk donors have changed over time and whether
sicker ACLF patients benefit from high-risk donor grafts. This
study aims to investigate trends of posttransplant outcomes in
ACLF patients.

MATERIALS AND METHODS
Patient Cohort
This study uses data from the Organ Procurement and
Transplantation Network and United Network for Organ
Sharing (OPTN/UNOS) in the Standard Transplant Analysis
and Research file, which includes data on all patients who
received an LT in the United States. Adult transplant patients
(≥18 y old at LT) between January 1, 2002, and March 31,
2019, were evaluated. Patients with status 1A or retransplant
or who underwent LT combined with thoracic organs, intestine, kidney, and pancreas were excluded (Figure 1).
Patients with ACLF were identified using the European
Association for the Study of the Liver-Chronic Liver Failure
criteria at the time of LT.1 In the OPTN/UNOS registry, specific OFs were assessed according to the presence of coagulopathy (international normalized ratio ≥2.5), liver failure
(total bilirubin ≥12 mg/dL), renal failure (creatinine ≥2.0 mg/
dL or dialysis), renal insufficiency (creatinine 1.5–1.9 mg/dL),
grade 3 through 4 encephalopathy, circulatory failure (vasopressor requirement), and respiratory failure (mechanical
ventilation requirement) in patients with a single manifestation of hepatic decompensation defined by either ascites or
encephalopathy. In addition, ACLF population was limited
to hospitalized patients based on the criteria reported in a
previous study.1 We categorized all patients into 3 grades of
ACLF based on the numbers of OFs at LT: ACLF-1 (single
renal failure, renal insufficiency with nonrenal OF, or grade

1 through 2 encephalopathy with nonrenal OF), ACLF-2 (2
OFs), and ACLF-3 (3 or more OFs).7,8,11
This study was approved for an institutional review board
waiver after an institutional review board review.
Trends in Posttransplant Outcomes Over Eras by
DRI Category
The primary endpoint was 1-y posttransplant patient survival. To assess the trend of outcomes over time in ACLF
patients, we categorized the study period into three 5-y eras:
Era 1 (2002–2007), Era 2 (2008–2013), and Era 3 (2014–
2019). Adjusted hazards of patient death within 1 y in Eras 2
and 3 were compared with Era 1 in the overall ACLF patient
cohort and within each DRI category. In this analysis, hazards were adjusted for recipient variables and donor variables
not included in the DRI formula. Recipient variables included
age, gender, body mass index (BMI), diabetes, ethnicity, primary diagnosis (hepatitis C virus [HCV; LI_DGN 4104, 4106,
4204, 4206, 4593], nonalcoholic steatohepatitis [NASH,
LI_DGN 4214], cholestatic liver disease [LI_DGN 42204265], alcohol-related liver disease [LI_DGN 4215-4217],
metabolic liver disease [LI_DGN 4300-4315], and others),
UNOS region, and ACLF grade 1 through 3. Donor variables
included BMI and gender. As a subgroup analysis, posttransplant outcome trends were also assessed in ACLF-1 combined
with ACLF-2 and ACLF-3.
Transplant outcomes over time have been affected by
advances in HCV therapy. Era 3 coincides with the emergence
of direct-acting antiviral agents and improved LT outcomes
in HCV-infected patients. Therefore, a subgroup analysis was
performed to assess the trends of posttransplant outcomes
according to HCV status.
Analysis of Adjusted Hazards of 1-Y Patient Death
Based on DRI in Each Era
Adjusted hazards of 1-y post-LT patient death in each
DRI category (DRI 1.2–1.6, 1.6–2.0, >2.0 [ref: 0–1.2]) were
analyzed using the Cox proportional hazards model. In this

FIGURE 1. Flow chart of study population selection. ACLF, acute-on-chronic liver failure; LT, liver transplant.

© 2022 The Author(s). Published by Wolters Kluwer Health, Inc.

analysis, hazards were adjusted for the same recipient‚ and
donor variables were used in the analysis over eras. As a subgroup analysis, adjusted hazards of patient death within 1 y in
each DRI category were also analyzed by ACLF-1 combined
with ACLF-2 and ACLF-3.
Analysis of Donor Risk Factors in Each Era
Donor risk factors for post-LT patient death within 1 y
were analyzed separately in each era in ACLF patients. Donor
risk factors were adjusted for recipient variables. Donor variables included age, gender, BMI, ethnicity, organ share (local,
regional, or national), donor type (donation after brain death
donor or donation after circulatory death [DCD] donor),
cold ischemia time (CIT), cause of death (trauma, anoxia,
or cerebrovascular accident), and graft type (whole or split
liver graft). As the cutoffs of CIT, 6 h (median), 8 h (75 percentile in this cohort), and 12 h were used.10 Recipient variables included age, gender, BMI, ethnicity, diabetes, primary
diagnosis, transplant type (liver alone or liver-kidney), UNOS
region, and ACLF grade 1 through 3.
Posttransplant Outcome Analysis in Patients With
Non-ACLF
One-year patient survival rates in each era and adjusted
hazards of 1-y patient death based on DRI category were separately analyzed in the non-ACLF population. Patients with
status 1A or retransplant or who underwent LT combined
with thoracic organs, intestine, kidney, and pancreas were
excluded (Figure 1). In this analysis, hazards were adjusted
for recipient variables and donor variables not included in
the DRI formula. Recipient variables included age, gender,
BMI, diabetes, ethnicity, primary diagnosis, UNOS region,
the Model for End-stage Liver Disease score, Karnofsky performance status score (10%–30%, 40%–60%, 70%–100%),
encephalopathy (none/grades 1–2 or grades 3–4), ascites
(absent/slight or moderate), life-support requirement, and
status of dialysis (yes/no). Donor variables included BMI and
gender.
Statistical Analysis
Data were summarized using the median with interquartile
range for continuous variables and percentages for discrete
variables. Comparisons of continuous variables and discrete
variables were performed using the Kruskal-Wallis test and
chi-square test, respectively. Patients were analyzed from time
of LT using the Kaplan-Meier method‚ and groups were compared with log-rank tests. Risk factors for posttransplant
patient death and the hazard risk were analyzed using Cox
proportional hazards models. A P < 0.05 was considered statistically significant. All statistical analyses were completed
using SPSS version 25 (IBM, Chicago, IL).

RESULTS
Patient Characteristics
A total of 17 300 patients with ACLF were evaluated. Of
these, 4032 (23.3%), 6130 (35.4%), and 7138 (41.3%) were
transplanted in Era 1, Era 2, and Era 3, respectively (Figure 1).
The following recipient characteristics were greater in Era 3
than in Era 1 and Era 2 (Table 1): median age (Era 1: 52.0
versus Era 2: 55.0 versus Era 3: 55.0 y; P < 0.001), Model for
End-stage Liver Disease score (33.0 versus 35.0 versus 36.0;
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P < 0.001), proportion of NASH (2.4% versus 9.3% versus
16.2%; P < 0.001) and alcohol-related liver disease (26.2%
versus 25.3% versus 37.3%; P < 0.001), diabetes (20.6% versus 23.1% versus 23.6%; P = 0.001), liver failure (36.8%
versus 38.6% versus 46.4%; P < 0.001), renal failure (32.1%
versus 32.5% versus 38.6%; P < 0.001), coagulopathy (26.0%
versus 27.6% versus 35.1%; P < 0.001), ACLF-2 (34.2% versus
37.0% versus 39.2%), and ACLF-3 (34.1% versus 34.1% versus 36.3%; P < 0.001). In ACLF patients undergoing transplant,
duration on the waitlist was shorter in Era 3 than in Eras 1 and
2 (20 versus 21 versus 13 d; P < 0.001).
In terms of donor characteristics, donors in Era 3, compared
with Eras 1 and 2, had higher BMI (25.6 versus 26.2 versus
26.7 kg/m2; P < 0.001) and shorter CIT (7.0 versus 6.2 versus 6.0 h; P < 0.001). In Era 3, there was a higher proportion
of donors with anoxia as the cause of death (13.3% versus
24.2% versus 35.3%; P < 0.001) and regional share donors
(23.4% versus 28.2% versus 52.4%; P < 0.001), whereas the
percent of split liver grafts (1.6% versus 0.8% versus 0.5%;
P < 0.001) was lower. The median volume of LT performed for
ACLF at each center increased significantly over time (64 versus 74 versus 91 cases per center per era; P = 0.017) (Table 1).
Trends in Posttransplant Outcomes Over Eras by
DRI Category
In ACLF patients, 1-y patient survival rates in Era 1, Era
2, and Era 3 have improved steadily from 80.4% to 85.2%
to 89.4%. All differences are statistically significant (P < 0.001;
Table S1, SDC, http://links.lww.com/TXD/A402). For ACLF-1
combined with ACLF-2, 1-y patient survival improved from
82.4% to 87.3% to 90.1% (P < 0.001)‚ and for ACLF-3
patients, 1-y patient survival increased from 76.5% to 81.1%
to 88.1% (P < 0.001). ACLF patients had significantly lower
risks of patient death within 1 y in Era 2 (adjusted hazard
ratio [aHR], 0.69; 95% confidence interval [CI], 0.61-0.78;
P < 0.001) and Era 3 (aHR, 0.48; 95% CI, 0.42-0.55; P < 0.001)
than in Era 1. When ACLF patients were stratified into the 4
DRI groups, all 4 groups had significantly lower adjusted risks
in Era 3 than in Era 1 (Table 2). In the subgroup analysis of
ACLF-1 and 2 patients combined, lower risks in Era 3 were
found in the overall, DRI 1.2 to 1.6‚ and DRI >2 categories.
ACLF-3 patients had significantly lower risks of patient death
within 1 y in Era 2 (aHR, 0.74; 95% CI, 0.61-0.89; P = 0.001)
and Era 3 (aHR, 0.43; 95% CI, 0.35-0.53; P < 0.001) than in
Era 1. The 2 DRI categories between 1.2 and 2.0 had significantly lower adjusted risks in Era 3 than in Era 1, whereas the
DRI >2.0 categories in Era 2 and Era 3 had risk comparable
to Era 1 (Table 2). For ACLF-3 patients who received a donor
graft with DRI between 1.6 and 2.0, 1-y patient survival went
from 75.9% to 78.1% to 86.9% (P < 0.001). One-year patient
survival rates in each Era based on the DRI group are shown in
Table S1 (SDC, http://links.lww.com/TXD/A402).
In the subgroup analysis of HCV patients, ACLF patients
overall and those with DRI 1.2 to 1.6 had significantly lower
adjusted risks of patient death within 1 y in Era 3 than in Era
1. A steady improvement was found in ACLF-1 and 2 with
DRI 1.2 to 1.6. ACLF-3 patients overall and those with
DRI 1.2 to 1.6 had lower risk in Era 3 than in Era 1 (Table
S2, SDC, http://links.lww.com/TXD/A402). In non-HCV
patients, overall ACLF patients and those with DRI >1.2 categories had significantly lower adjusted risks of patient death
within 1 y in Era 3 than in Era 1. A steady improvement was
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TABLE 1.

Characteristics at transplant in patients with ACLF

Recipient characteristics
Age (y), median [IQR]
Gender n, (%)
BMI (kg/m2), median [IQR]
Ethnicity n, (%)

Diagnosis n, (%)

Diabetes n, (%)
Liver failure n, (%)
Renal failure n, (%)
Respiratory failure n, (%)
Coagulopathy n, (%)
MELD score, median [IQR]
ACLF grades, n (%)

Days on waitlist (d), median [IQR]
Transplant centers, n
Case numbers of ACLF at each center, median [IQR]
Donor characteristics
Age (y), median [IQR]
Gender n, (%)
BMI (kg/m2), median [IQR]
Ethnicity n, (%)

Cause of death n, (%)

Donor type n, (%)

Allocation type n, (%)

Male
Female
White
Black
Others
HCV
NASH
CLD
ALD
Metabolic
Others

ACLF-1
ACLF-2
ACLF-3

Male
Female
White
Black
Others
Trauma
Anoxia
Cerebrovascular
Others
DBD
DCD
LDLT
Local
Regional
National

Split graft n, (%)
CIT (h), median [IQR]
DRI, median [IQR]

Era 1
2002–2007
(n = 4032)

Era 2
2008–2013
(n = 6130)

Era 3
2014–2019
(n = 7138)

52.0 [46.0–58.0]
2674 (66.3)
1358 (33.7)
27.7 [24.4–32.1]
2761 (68.5)
343 (8.5)
928 (23.0)
1247 (30.9)
95 (2.4)
305 (7.6)
1057 (26.2)
80 (2.0)
1248 (31.0)
796 (20.6)
1485 (36.8)
1293 (32.1)
302 (7.5)
1047 (26.0)
33.0 [28.0–39.0]
1277 (31.7)
1379 (34.2)
1376 (34.1)
20 [6–152]
108
64 [28–117]

55.0 [49.0–60.0]
3904 (63.7)
2226 (36.3)
28.7 [25.1–33.0]
4153 (67.7)
598 (9.8)
1379 (22.5)
1845 (30.1)
570 (9.3)
489 (8.0)
1552 (25.3)
147 (2.4)
1527 (24.9)
1401 (23.1)
2367 (38.6)
1995 (32.5)
351 (5.7)
1693 (27.6)
35.0 [30.0–40.0]
1774 (28.9)
2268 (37.0)
2088 (34.1)
21 [6–155]
117
74 [36–140]

55.0 [47.0–61.0]
4291 (60.1)
2847 (39.9)
29.1 [25.3–33.7]
4864 (68.1)
557 (7.8)
1717 (24.1)
1005 (14.1)
1156 (16.2)
527 (7.4)
2665 (37.3)
160 (2.2)
1625 (22.8)
1678 (23.6)
3310 (46.4)
2758 (38.6)
433 (6.1)
2506 (35.1)
36.0 [32.0–40.0]
1749 (24.5)
2799 (39.2)
2590 (36.3)
13 [4–83]
118
91 [44–144]

<0.001
<0.001

41.0 [24.0–54.0]
2440 (60.5)
1592 (39.5)
25.6 [22.6–29.2]
2754 (68.3)
480 (11.9)
798 (19.8)
1655 (41.0)
535 (13.3)
1706 (42.3)
136 (3.4)
3866 (95.9)
127 (3.1)
39 (1.0)
2904 (72.0)
945 (23.4)
183 (4.5)
66 (1.6)
7.0 [5.2–9.0]
1.5 [1.3–1.8]

40.0 [26.0–53.0]
3613 (58.9)
2517 (41.1)
26.2 [23.1–30.2]
3894 (63.5)
952 (15.5)
1284 (20.9)
2193 (35.8)
1484 (24.2)
2278 (37.2)
175 (2.9)
5896 (96.2)
204 (3.3)
30 (0.5)
4250 (69.3)
1726 (28.2)
154 (2.5)
50 (0.8)
6.2 [5.0–8.0]
1.5 [1.3–1.8]

38.0 [27.0–52.0]
4349 (60.9)
2789 (39.1)
26.7 [23.4–30.8]
4437 (62.2)
1157 (16.2)
1544 (21.6)
2308 (32.3)
2521 (35.3)
2113 (29.6)
196 (2.7)
6918 (96.9)
189 (2.6)
31 (0.4)
3288 (46.1)
3740 (52.4)
110 (1.5)
34 (0.5)
6.0 [4.8–7.4]
1.5 [1.3–1.7]

0.080
0.056

P

<0.001
0.001

<0.001

0.001
<0.001
<0.001
0.001
<0.001
<0.001
<0.001

<0.001
–
0.017

<0.001
<0.001

<0.001

0.001

<0.001

<0.001
<0.001
<0.001

Bold type indicates statistically significant differences.
ACLF, acute-on-chronic liver failure; ALD, alcohol-related liver disease; BMI, body mass index; CIT, cold ischemia time; CLD, cholestatic liver disease; DBD, donation after brain death; DCD, donation
after circulatory death; DRI, donor risk index; HCV, hepatitis C virus; IQR, interquartile range; MELD, model for end-stage liver disease; NASH, nonalcoholic steatohepatitis.

reproduced for each ACLF grade (Table S3, SDC, http://links.
lww.com/TXD/A402).
Adjusted Hazards of Patient Death Within 1 Y Based
on DRI Category in Each Era
In the overall ACLF cohort, the 2 categories with DRI >1.6
had significantly higher adjusted risks of 1-y patient death.

When analyzing hazards in each era, DRI >2.0 carried significantly higher adjusted risks in Era 1 and 3‚ whereas DRI
1.2 to 2.0 had similar adjusted risks compared with DRI
0 to 1.2 throughout eras (Figure 2).
In the subgroup analysis of ACLF-1 and 2, DRI >2.0 had
higher adjusted risk of patient death in each era. Adjusted HRs
have decreased in the DRI >2.0 category over time (Figure S1,

© 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
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TABLE 2.

Adjusted hazards of 1-y patient death in each DRI category according to eras (ref: Era 1 [2002–2007])
Era 2 (2008–2013)

Era 3 (2014–2019)

aHR (95% CI)
Overall ACLF
Overall
0 < DRI ≦ 1.2
1.2 < DRI ≦ 1.6
1.6 < DRI ≦ 2.0
2.0 < DRI
ACLF-1 and 2
Overall
0 < DRI ≦ 1.2
1.2 < DRI ≦ 1.6
1.6 < DRI ≦ 2.0
2.0 < DRI
ACLF-3
Overall
0 < DRI ≦ 1.2
1.2 < DRI ≦ 1.6
1.6 < DRI ≦ 2.0
2.0 < DRI
Non-ACLF
Overall
0 < DRI ≦ 1.2
1.2 < DRI ≦ 1.6
1.6 < DRI ≦ 2.0
2.0 < DRI

P

aHR (95% CI)

P

0.69 (0.61-0.78)
0.90 (0.60-1.36)
0.64 (0.53-0.76)
0.92 (0.72-1.17)
0.68 (0.49-0.94)

<0.001
0.623
<0.001
0.483
0.019

0.48 (0.42-0.55)
0.60 (0.39-0.94)
0.39 (0.32-0.48)
0.70 (0.54-0.90)
0.61 (0.43-0.87)

<0.001
0.025
<0.001
0.005
0.006

0.66 (0.57-0.77)
0.73 (0.43-1.23)
0.70 (0.55-0.90)
0.91 (0.66-1.26)
0.62 (0.42-0.92)

<0.001
0.236
0.005
0.572
0.016

0.52 (0.44-0.62)
0.66 (0.39-1.14)
0.47 (0.36-0.63)
0.80 (0.58-1.12)
0.51 (0.33-0.78)

<0.001
0.137
<0.001
0.197
0.002

0.74 (0.61-0.89)
1.52 (0.75-3.07)
0.56 (0.42-0.73)
0.95 (0.66-1.36)
0.98 (0.52-1.85)

0.001
0.244
<0.001
0.786
0.955

0.43 (0.35-0.53)
0.59 (0.27-1.31)
0.31 (0.23-0.43)
0.59 (0.40-0.87)
0.86 (0.45-1.66)

<0.001
0.194
<0.001
0.008
0.648

0.69 (0.64-0.75)
0.90 (0.66-1.22)
0.71 (0.62-0.81)
0.71 (0.62-0.83)
0.68 (0.57-0.82)

<0.001
0.490
<0.001
<0.001
<0.001

0.47 (0.43-0.52)
0.66 (0.48-0.92)
0.47 (0.40-0.55)
0.51 (0.44-0.61)
0.44 (0.36-0.54)

<0.001
0.013
<0.001
<0.001
<0.001

Bold type indicates statistically significant differences.
ACLF, acute-on-chronic liver failure; aHR, adjusted hazard ratio; CI, confidence interval; DRI, donor risk index.

SDC, http://links.lww.com/TXD/A402). In patients with
ACLF-3, DRI 1.2 to 1.6 in Era 1 and DRI >2.0 in Era 3 were
associated with an increased risk of 1-y patient death, whereas
in Era 2, no DRI groups were associated with risk (Figure S2,
SDC, http://links.lww.com/TXD/A402).
Subgroup Analysis of Posttransplant Outcomes Over
Era by DCD Status
In 17 300 ACLF patients, 520 patients (3.0%) received a
graft from a DCD donor. In ACLF patients who received a
graft from a DCD donor, Era 2 (aHR, 0.85; 95% CI, 0.431.68; P = 0.64) and Era 3 (aHR, 0.60; 95% CI, 0.27-1.34;
P = 0.21) had similar aHRs of patient death within 1 y compared with Era 1. In ACLF patients without a DCD donor, Era
2 (aHR, 0.74; 95% CI, 0.65-0.84; P < 0.001) and Era 3 (aHR,
0.53; 95% CI, 0.46-0.62; P < 0.001) had significantly lower
risks than Era 1.
Donor Risk Factors for Patient Death Within 1 Y in
Each Era
In the overall ACLF cohort, donor factors associated with
1-y patient death on multivariate analysis include older donor
age (51–60, 61–70, >70 y), DCD donor, prolonged CIT (6–8,
8–12 h), and CVA as the cause of death. When analyzing
donor risk factors in each era separately, older donor age (51–
60, 61–70, >70 y), Black donor race, DCD donor, and CIT
8 to 12 h remained independent risk factors in Era 3. The risks
of CIT 6 to 8 h and CVA as the cause of death have diminished
over time, and these were no longer independent risk factors
in Era 3 (Table 3).

Posttransplant Outcomes in Patients Without ACLF
In non-ACLF patients, 1-y patient survival rates in Era 1,
Era 2, and Era 3 have improved steadily from 89.5% to
91.7% to 93.6%. Patient survival rates in DRI categories
were summarized in Table S1 (SDC, http://links.lww.com/
TXD/A402). Non-ACLF patients had significantly lower risks
of patient death within 1 y in Era 2 (aHR, 0.69; 95% CI,
0.64-0.75; P < 0.001) and Era 3 (aHR, 0.47; 95% CI, 0.430.52; P < 0.001) than in Era 1. When non-ACLF patients were
stratified into the 4 DRI categories, all 4 categories had significantly lower adjusted risks in Era 3 than in Era 1 (Table 2).

DISCUSSION
In this study, we demonstrate that posttransplant outcomes
have significantly improved over time both in ACLF and nonACLF patients. ACLF patients with DRI 1.2 to 1.6 had lower
risk of patient death in Era 2 and 3 than in Era 1 regardless of ACLF grades. Those with DRI >2.0 had lower risk of
patient death in Eras 2 and 3 than in Era 1 in ACLF-1 and
2‚ whereas this finding was not observed in ACLF-3. In the
overall ACLF cohort, adjusted hazards of patients with DRI
1.2 to 1.6 grafts have decreased over time. In ACLF-1 and 2,
the similar results were obtained‚ whereas in ACLF-3, no association between risks of patient death in each DRI category
and eras was found. Our findings suggest that the improvement in posttransplant outcomes was observed in the ACLF
cohort and the appropriate use of moderate-risk donors (DRI,
1.2–1.6) for ACLF patients may increase access to transplant
without compromising posttransplant outcomes. Although
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FIGURE 2. Adjusted hazards of 1-y patient death in each DRI category in ACLF (ref: 0 < DRI ≦ 1.2). A, Overall (2002–2019). B, Era 1 (2002–
2007). C, Era 2 (2008–2013). D, Era 3 (2014–2019). ACLF, acute-on-chronic liver failure; aHR, adjusted hazard ratio; DRI, donor risk index.

special caution should be taken for the use of high-risk donors
(DRI >2.0), the findings allow for a wider acceptance of marginal grafts in ACLF patients.
There are several reasons for the improvement in posttransplant outcomes. Performing LT in critically ill ACLF
patients with higher-risk grafts represents a significant challenge to transplant centers. ACLF patients require specialized care that includes the identification and treatment of
precipitating factors, stabilization of the patient, rapid and
accurate risk assessment for LT, appropriate donor selection, and optimal perioperative management. The current
data document a clear increase in ACLF volume per center
over time‚ and centers have undoubtedly benefitted from this
experience. Transplant center experience has been associated
with improved outcomes in patients with acute liver failure.12
Specific and standardized improvements in the care of critically ill cirrhotic patients have also undoubtedly helped with
improved posttransplant outcomes.13,14 Given the younger
donor age, shorter CIT, and lower proportion of national

donors seen in Era 3, we considered that the improvement
might be attributable to careful donor selection at transplant
centers. One factor that does not appear to be the primary
reason for improved outcomes is the use of direct-acting antiviral therapy for HCV patients in Era 315,16 in that comparable
improvement over time were seen in both HCV and non-HCV
patients.
In addition, it was reported that post-LT outcomes with
extended criteria donors‚ such as older donors or DCD donors‚
have been improving over time.10,17-19 This improvement has
been driven by a better understanding of how to successfully utilize these organs through better donor and recipient
matching and the refinement of the procurement operation.19
In this study, to address the effect of DCD grafts, we have
analyzed trends of posttransplant outcomes in ACLF patients
according to the presence of DCD donors. We showed that
DCD donors were used only in 3.0% of ACLF patients, and
posttransplant outcomes have improved over time regardless
of DCD or donation after brain death donors. Based on this

© 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
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TABLE 3.

Multivariable analysis of donor risk factors for 1-y patient death in ACLF patients
Overall
(2002–2019)
aHR (95% CI)
Age (y)

Gender
BMI (kg/m2)

Ethnicity

Organ share

Donor type
CIT (h)

Cause of death

Graft type

≤40
41–50
51–60
61–70
70<
Male
Female
<18.5
18.5–24.9
25.0–29.0
≥30
White
Black
Others
Local
Regional
National
DBD
DCD
≤6
6–8
8–12
>12
Trauma
Anoxia
CVA
Whole
Split

Ref
1.15 (1.00-1.33)
1.22 (1.06-1.41)
1.57 (1.31-1.88)
2.03 (1.51-2.75)
Ref
1.04 (0.93-1.15)
0.77 (0.53-1.10)
Ref
0.90 (0.80-1.02)
0.88 (0.77-0.99)
Ref
1.08 (0.94-1.25)
1.10 (0.96-1.25)
Ref
0.88 (0.79-0.99)
1.10 (0.83-1.46)
Ref
1.77 (1.37-2.29)
Ref
1.14 (1.01-1.28)
1.39 (1.22-1.59)
1.36 (0.98-1.88)
Ref
1.08 (0.94-1.25)
1.23 (1.07-1.41)
Ref
1.24 (0.70-2.20)

Era 1
(2002–2007)
P
0.050
0.007
<0.001
<0.001
0.502
0.149
0.087
0.042
0.285
0.165
0.026
0.505
<0.001
0.035
<0.001
0.065
0.253
0.003
0.466

aHR (95% CI)
Ref
1.16 (0.88-1.52)
1.07 (0.80-1.44)
1.43 (1.02-2.02)
1.50 (0.91-2.46)
Ref
0.83 (0.67-1.02)
1.07 (0.59-1.94)
Ref
0.81 (0.64-1.02)
0.97 (0.75-1.24)
Ref
1.19 (0.88-1.61)
1.18 (0.92-1.51)
Ref
0.98 (0.77-1.24)
1.08 (0.68-1.72)
Ref
1.51 (0.92-2.50)
Ref
1.13 (0.88-1.44)
1.37 (1.07-1.76)
1.45 (0.91-2.32)
Ref
1.14 (0.83-1.57)
1.39 (1.08-1.79)
Ref
1.18 (0.48-2.90)

Era 2
(2008–2013)
P
0.304
0.654
0.041
0.112
0.075
0.825
0.070
0.786
0.249
0.204
0.845
0.754
0.105
0.353
0.012
0.118
0.430
0.010
0.718

aHR (95% CI)
Ref
1.09 (0.87-1.36)
1.22 (0.97-1.53)
1.45 (1.09-1.91)
1.85 (1.12-3.06)
Ref
1.08 (0.92-1.27)
0.56 (0.30-1.06)
Ref
0.92 (0.76-1.10)
0.84 (0.69-1.03)
Ref
0.84 (0.66-1.06)
1.15 (0.94-1.41)
Ref
0.90 (0.75-1.08)
1.14 (0.73-1.78)
Ref
1.91 (1.32-2.78)
Ref
1.14 (0.96-1.37)
1.22 (0.99-1.51)
0.83 (0.45-1.54)
Ref
1.11 (0.89-1.38)
1.30 (1.05-1.62)
Ref
0.94 (0.35-2.53)

Era 3
(2014–2019)
P
0.445
0.086
0.010
0.017
0.360
0.076
0.346
0.099
0.140
0.171
0.250
0.566
0.001
0.145
0.064
0.560
0.376
0.016
0.896

aHR (95% CI)
Ref
1.18 (0.92-1.51)
1.30 (1.01-1.67)
1.76 (1.28-2.44)
2.70 (1.48-4.91)
Ref
1.15 (0.96-1.38)
0.77 (0.39-1.50)
Ref
1.01 (0.82-1.25)
0.92 (0.73-1.15)
Ref
1.45 (1.15-1.82)
1.05 (0.83-1.32)
Ref
1.11 (0.92-1.34)
1.11 (0.60-2.06)
Ref
1.67 (1.01-2.78)
Ref
1.04 (0.85-1.28)
1.29 (1.01-1.65)
1.59 (0.74-3.38)
Ref
1.22 (0.97-1.53)
1.02 (0.79-1.31)
Ref
1.65 (0.52-5.21)

P
0.191
0.042
0.001
0.001
0.141
0.435
0.919
0.440
0.002
0.702
0.279
0.735
0.048
0.681
0.041
0.233
0.091
0.904
0.392

Bold type indicates statistically significant differences.
ACLF, acute-on-chronic liver failure; aHR, adjusted hazard ratio; BMI, body mass index; CI, confidence interval; CIT, cold ischemia time; CVA, cerebrovascular accident; DBD, donation after brain death;
DCD, donation after circulatory death.

finding, we considered that the improvement of outcomes in
ACLF patients might not be related to the improved outcomes
of LT from DCD donors. In our cohort, improvement was
also found in non-ACLF patients‚ which is consistent with
previous reports.10,20 This improvement in the general population in the modern era could be one of the reasons for the
improvement of outcomes in ACLF patients.
We did find a decrease in time on the waiting list for transplanted recipients especially in Era 3‚ and this may have
contributed to the improved outcomes. ACLF patients experience organ damage that can worsen with time‚ and ACLF-3
patients have significant 30-d waitlist mortality. One study
of improved transplant outcomes in ACLF-3 patients noted
a median time from listing to transplant of 8 d.4 A previous
analysis of ACLF patients in the UNOS registry noted that LT
within 30 d of listing was associated with an improved
outcome.7
Specific donor risk factors associated with patient death
within 1 y were defined in each era. It is important to note that
older donor grafts (>51 y), grafts from Black donors, DCD
grafts‚ and grafts with prolonged CIT (8–12 h) remained independent risk factors in Era 3. Although an improvement in
posttransplant outcomes in ACLF population was found over
time, the use of grafts with higher DRI (>2.0) is still associated

with an increased risk of patient death within 1 y in this era.
It might be noted that ACLF-3 patients receiving grafts with
DRI >2.0 in Era 3 still had 1-y patient survival of 78.8%‚
which markedly exceeds a reported 1-y survival of 7.9%
without LT4; however, LT in this setting would come across
issues of cost, organ utilization‚ and regulatory guardrails for
expected outcomes. Centers will have to weigh the risks of
higher-risk donors with the risks of longer waiting times on a
case-by-case basis.
Since 2006, DRI has been used as a useful metric of donor
quality in multiple studies and enhanced our understanding
of donor factors and their impact on outcomes.21 This index
has helped the decision-making process during an organ offer;
however, DRI was derived from data before the Model for
End-stage Liver Disease era, and it has been reported that there
are some limitations of donor quality evaluation using DRI in
the recent era because of the change of recipient and donor
characteristics,21 policy changes over the decades,22,23 and the
improvement of LT outcomes with the use of extended criteria
donor grafts.10 In this study, CIT 6 to 8 and >12 h, organ share
(local/regional/national), cause of donor death, and graft type
(whole/split) did not relate to patient survival after LT in Era
3. This finding suggests that further research is encouraged to
update DRI to reflect these changes in the current era.
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There are limitations of this study that bear comment. First,
both posttransplant and waitlist outcomes need to be taken
into account to assess the prognostic impact of LT; however,
intention-to-treat survival in ACLF patients is difficult to evaluate because ACLF is a dynamic syndrome and their ACLF
status might be changed during the waiting time.11 Second,
each OF, ascites, or encephalopathy might be misclassified or
underestimated in the UNOS registry because this information is based on subjective evaluation. Third, some clinical
information necessary for defining ACLF (such as the onset of
ACLF) and selecting or grading ACLF patients is unavailable
in the UNOS registry. Decompensating events such as variceal
hemorrhage are not captured. We used mechanical ventilation
as a surrogate marker of respiratory failure based on previous studies.7,8 Although macrosteatosis in the graft is reported
to be associated with worse posttransplant outcomes,24 it
is not included in the DRI and is not included in this study
because of a large number of missing values in the UNOS
registry. Fourth, although we created 5-y era groups to evaluated possible trends of posttransplant outcomes to equalize
the number of patients in each era group, there have been
several changes in the liver graft allocation system22,23 during
this study period‚ which could have affected posttransplant
outcomes. We selected the ACLF cohort based on their clinical
status at the time of transplant but not at the time of listing.
Therefore, the recent changes in the liver allocation would not
necessarily affect their posttransplant outcomes. In addition,
other important outcome metrics such as cost and complication rates are beyond the scope of this analysis. Despite these
limitations, this is the first study investigating the trend of the
outcomes with the use of higher-risk donors in ACLF patients
by utilizing the UNOS registry.
In conclusion, our study demonstrated that posttransplant outcomes have significantly improved over time despite
increased acuity of illness in ACLF patients. The use of marginal liver grafts might be considered rather than waiting for
the use of ideal grafts for ACLF patients. Although the use of
marginal grafts with multiple risk factors should be considered judiciously, our results suggest the potential to expand
the donor pool and transplant access for ACLF patients while
maintaining excellent transplant outcomes.

ACKNOWLEDGMENTS
The UNOS has supplied the data reported here as the contractor for the OPTN. The interpretation and reporting of
these data are the responsibility of the authors and in no way
should be seen as an official policy of or interpretation by the
OPTN or the US government.

REFERENCES
1. Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a
distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144:1426–1437, 1437.
e1421–1429.

www.transplantationdirect.com

2. Shi Y, Yang Y, Hu Y, et al. Acute-on-chronic liver failure precipitated by
hepatic injury is distinct from that precipitated by extrahepatic insults.
Hepatology (Baltimore, Md). 2015;62:232–242.
3. Arroyo V, Moreau R, Jalan R, et al. Acute-on-chronic liver failure: a
new syndrome that will re-classify cirrhosis. J Hepatol. 2015;62(Suppl
1):S131–S143.
4. Artru F, Louvet A, Ruiz I, et al. Liver transplantation in the most severely
ill cirrhotic patients: a multicenter study in acute-on-chronic liver failure
grade 3. J Hepatol. 2017;67:708–715.
5. Sundaram V, Shah P, Wong RJ, et al. Patients with acute on chronic
liver failure grade 3 have greater 14-day waitlist mortality than status1a patients. Hepatology (Baltimore, Md). 2019;70:334–345.
6. Thuluvath PJ, Thuluvath AJ, Hanish S, et al. Liver transplantation
in patients with multiple organ failures: feasibility and outcomes. J
Hepatol. 2018;69:1047–1056.
7. Sundaram V, Jalan R, Wu T, et al. Factors associated with survival of
patients with severe acute-on-chronic liver failure before and after liver
transplantation. Gastroenterology. 2019;156:1381–1391.e1383.
8. Sundaram V, Mahmud N, Perricone G, et al. Long-term outcomes
of patients undergoing liver transplantation for acute-on-chronic liver
failure. Liver Transpl. 2020;26:1594–1602.
9. Karvellas CJ, Francoz C, Weiss E. Liver transplantation in acute-onchronic liver failure. Transplantation. 2021;105:1471–1481.
10. Zhang T, Dunson J, Kanwal F, et al. Trends in outcomes for marginal
allografts in liver transplant. JAMA Surg. 2020;155:926–932.
11. Sundaram V, Kogachi S, Wong RJ, et al. Effect of the clinical course
of acute-on-chronic liver failure prior to liver transplantation on posttransplant survival. J Hepatol. 2020;72:481–488.
12. Wong NZ, Schaubel DE, Reddy KR, et al. Transplant center experience influences spontaneous survival and waitlist mortality in acute
liver failure: an analysis of the UNOS database. Am J Transplant.
2021;21:1092–1099.
13. McPhail MJ, Shawcross DL, Abeles RD, et al. Increased survival for
patients with cirrhosis and organ failure in liver intensive care and validation of the chronic liver failure-sequential organ failure scoring system. Clin Gastroenterol Hepatol. 2015;13:1353–1360.e1358.
14. Nadim MK, Durand F, Kellum JA, et al. Management of the critically
ill patient with cirrhosis: a multidisciplinary perspective. J Hepatol.
2016;64:717–735.
15. Flemming JA, Kim WR, Brosgart CL, et al. Reduction in liver transplant
wait-listing in the era of direct-acting antiviral therapy. Hepatology
(Baltimore, Md). 2017;65:804–812.
16. Nagai S, Collins K, Chau LC, et al. Increased risk of death in first
year after liver transplantation among patients with nonalcoholic
steatohepatitis vs liver disease of other etiologies. Clin Gastroenterol
Hepatol. 2019;17:2759–2768.e2755.
17. Haugen CE, Holscher CM, Luo X, et al. Assessment of trends in
transplantation of liver grafts from older donors and outcomes in
recipients of liver grafts from older donors, 2003-2016. JAMA Surg.
2019;154:441–449.
18. Croome KP, Lee DD, Keaveny AP, et al. Improving national results
in liver transplantation using grafts from donation after cardiac death
donors. Transplantation. 2016;100:2640–2647.
19. Croome KP, Taner CB. The changing landscapes in DCD liver transplantation. Curr Transplant Rep. 2020:1–11.
20. Kwong AJ, Kim WR, Lake JR, et al. OPTN/SRTR 2019 annual data
report: liver. Am J Transplant. 2021;21(Suppl 2):208–315.
21. Flores A, Asrani SK. The donor risk index: a decade of experience.
Liver Transpl. 2017;23:1216–1225.
22. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med.
2008;359:1018–1026.
23. Feng S, O’Grady J. Share 35: a liver in time saves lives? Am J
Transplant. 2015;15:581–582.
24. Spitzer AL, Lao OB, Dick AA, et al. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl.
2010;16:874–884.

